Rachel Thijssen

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L Garnham, Jafar S Jabbari, Hongke Peng, Thomas E Lew, Charis E Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M Djajawi, Constantine S Tam, John F Seymour, Piers Blombery, Daniel HD Gray, Ian J Majewski, Matthew E Ritchie, et al.

Journal article  |  2022  |  BLOOD

Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leuke..

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R Thompson, Tamia Nguyen, Yamuna Kankanige, John F Markham, Mary Ann Anderson, Sasanka M Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S Tam, John F Seymour, Andrew W Roberts, David A Westerman, Piers Blombery

Journal article  |  2022  |  BLOOD ADVANCES

The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex ..

Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing

Luyi Tian, Jafar S Jabbari, Rachel Thijssen, Quentin Gouil, Shanika L Amarasinghe, Oliver Voogd, Hasaru Kariyawasam, Mei RM Du, Jakob Schuster, Changqing Wang, Shian Su, Xueyi Dong, Charity W Law, Alexis Lucattini, Yair David Joseph Prawer, Coralina Collar-Fernandez, Jin D Chung, Timur Naim, Audrey Chan, Chi Hai Ly, et al.

Journal article  |  2021  |  GENOME BIOLOGY

A modified Chromium 10x droplet-based protocol that subsamples cells for both short-read and long-read (nanopore) sequencing toget..

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljic, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, et al.

Journal article  |  2021  |  BLOOD

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemi..

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Ella R Thompson, Tamia Nguyen, Yamuna Kankanige, Mary Ann Anderson, Sasanka M Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S Tam, John F Seymour, Andrew W Roberts, David Alan Westerman, Piers Blombery

Conference Proceedings  |  2020  |  BLOOD

Progression of chronic lymphocytic leukemia (CLL) on venetoclax (VEN) and BTK inhibitors (BTKi) is associated with acquired genomi..

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, R Thijssen, G Pomilio, A Ivey, JM Salmon, C Glytsou, SA Fleming, Q Zhang, H Ma, KP Patel, SM Kornblau, Z Xu, CC Chua, Xufeng Chen, P Blombery, et al.

Journal article  |  2020  |  BLOOD

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for..

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  BLOOD

There is a Blood Commentary on this article in this issue.

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma

Michael A Dengler, Charis E Teh, Rachel Thijssen, Lahiru Gangoda, Ping Lan, Marco J Herold, Daniel H Gray, Gemma L Kelly, Andrew W Roberts, Jerry M Adams

Journal article  |  2020  |  ONCOGENE

Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime..

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, Ella Thompson, Nguyen Tamia, Xiangting Chen, Michelle McBean, Richard W Birkinshaw, Peter E Czabotar, Rachel Thijssen, Mary Ann Anderson, John F Seymour, David Alan Westerman, David CS Huang, Andrew W Roberts

Conference Proceedings  |  2019  |  BLOOD

The BCL2 Gly101Val mutation may be acquired in patients with chronic lymphocytic leukaemia (CLL) treated with venetoclax (VEN), le..

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Rachel Thijssen, Andrew W Roberts

Journal article  |  2019  |  CANCER CELL

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy meta..